Prediction of Early Recurrence of Hepatocellular Carcinoma in Patients with Cirrhosis Who Had Received Deceased Donor Liver Transplantation: A Multicenter Study

被引:3
作者
Al-Ameri, Abdulahad Abdulrab Mohammed [1 ,2 ]
Wei, Xuyong [1 ,2 ]
Liu, Peng [1 ,2 ]
Lin, Lidan [3 ]
Shao, Zhou [1 ,2 ]
Xie, Haiyang [1 ,2 ]
Zhou, Lin [1 ,2 ]
Zheng, Shusen [1 ,2 ,3 ]
Xu, Xiao [1 ,2 ,3 ]
机构
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Div Hepatobiliary & Pancret Surg, Hangzhou, Zhejiang, Peoples R China
[2] NHFPC Key Lab Combined Multiorgan Transplatat, Hangzhou, Zhejiang, Peoples R China
[3] China Liver Transplant Registry, Shenzhen, Guangdong, Peoples R China
基金
中国博士后科学基金;
关键词
Carcinoma; Hepatocellular; Liver Cirrhosis; Liver Transplantation; Prognosis; Recurrence; HANGZHOU CRITERIA; VALIDATION; MODEL; COHORT; SCORE; HCC;
D O I
10.12659/AOT.917296
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Early recurrence after liver transplantation (LT) is still a clinical problem. This multicenter study evaluated the Milan, Hangzhou, and AFP model-based criteria for prediction of early recurrence of HCC in patients with cirrhosis who had undergone LT. Material/Methods: From the China Liver Transplant Registry (CLTR) database, we analyzed data of 589 HCC patients who had undergone LT between Jan 2015 and Jan 2019. Imaging data and AFP levels were evaluated immediately before LT. Recurrence and overall survival rates at 2 years were tested using the Kaplan-Meier estimate. The Milan criteria, Hangzhou criteria, and AFP model-based criteria were evaluated. Results: We found that 62.0%, 91.2%, and 67.6% of patients were within the Milan criteria, Hangzhou criteria, and AFP model-based criteria, respectively. The 2-year recurrence rate was 8.9%, 15.8%, and 11.8% with corresponding overall survival of 85.3%, 82.7%, and 86.5%, respectively. The 2-year recurrence rate was different in patients fulfilling and exceeding the AFP model-based criteria among patients who met either the Milan criteria (7.9% vs. 18.8%, HR=3.83, p=0.006) or Hangzhou criteria (12.0% vs. 27.6%, HR=2.95, p<0.001). However, the 2-year recurrence rate was not significantly different among patients who were beyond either the Milan or Hangzhou criteria. Conclusions: For the prediction of early recurrence of HCC in patients with cirrhosis after liver transplantation, Milan criteria, Hangzhou criteria, and AFP model-based criteria are effective predictive tools for stratification of patients into low- and high-risk groups of recurrence with different prognoses. The AFP model-based criteria can identify a subgroup of patients with high risk of recurrence among patients who met either Milan or Hangzhou criteria.
引用
收藏
页码:489 / 498
页数:10
相关论文
共 50 条
  • [1] Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation
    Fisher, R. A.
    Kulik, L. M.
    Freise, C. E.
    Lok, A. S. F.
    Shearon, T. H.
    Brown, R. S., Jr.
    Ghobrial, R. M.
    Fair, J. H.
    Olthoff, K. M.
    Kam, I.
    Berg, C. L.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (06) : 1601 - 1608
  • [2] Evaluation of the Alpha-Fetoprotein Model for Predicting Recurrence and Survival in Patients With Hepatitis B Virus (HBV)-Related Cirrhosis Who Received Liver Transplantation for Hepatocellular Carcinoma
    Ren, Ao
    Li, Zhongqiu
    Zhou, Xiaozhuan
    Zhang, Xuzhi
    Huang, Xiaochun
    Deng, Ronghai
    Ma, Yi
    FRONTIERS IN SURGERY, 2020, 7
  • [3] Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation
    Xiao, Guang-Qin
    Song, Jiu-Lin
    Shen, Shu
    Yang, Jia-Yin
    Yan, Lu-Nan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (31) : 10953 - 10959
  • [4] Recurrence risk prediction models for hepatocellular carcinoma after liver transplantation
    Zhang, Xu
    Chen, Chi
    Wang, Yan
    Xu, Jun
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (11) : 2272 - 2280
  • [5] Living Donor Liver Transplantation in Patients Who Have Received Pretransplant Treatment for Hepatocellular Carcinoma
    Yoshizumi, Tomoharu
    Shirabe, Ken
    Soejima, Yuji
    Taketomi, Akinobu
    Ikegami, Toru
    Uchiyama, Hideaki
    Harada, Noboru
    Ijichi, Hideki
    Maehara, Yoshihiko
    TRANSPLANTATION, 2011, 91 (08) : E61 - E62
  • [6] Systematic review: risk prediction models for recurrence of hepatocellular carcinoma after liver transplantation
    Al-Ameri, Abdulahad Abdulrab Mohammed
    Wei, Xuyong
    Wen, Xue
    Wei, Qiang
    Guo, Haijun
    Zheng, Shusen
    Xu, Xiao
    TRANSPLANT INTERNATIONAL, 2020, 33 (07) : 697 - 712
  • [7] Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation
    Guang-qin Xiao
    Jiu-lin Song
    Shu Shen
    Jia-yin yang
    lu-nan yan
    World Journal of Gastroenterology, 2014, (31) : 10953 - 10959
  • [8] Prediction of early recurrence of hepatocellular carcinoma after liver transplantation based on computed tomography radiomics nomogram
    Zhao, Jing-Wei
    Shu, Xin
    Chen, Xiao-Xia
    Liu, Jia-Xiong
    Liu, Mu-Qing
    Ye, Ju
    Jiang, Hui-Jie
    Wang, Gui-Sheng
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2022, 21 (06) : 543 - 550
  • [9] Ischemia-reperfusion injury and the risk of hepatocellular carcinoma recurrence after deceased donor liver transplantation
    Grat, Michal
    Krawczyk, Marek
    Wronka, Karolina M.
    Stypulkowski, Jan
    Lewandowski, Zbigniew
    Wasilewicz, Michal
    Krawczyk, Piotr
    Grat, Karolina
    Patkowski, Waldemar
    Zieniewicz, Krzysztof
    SCIENTIFIC REPORTS, 2018, 8
  • [10] Long-term outcomes of deceased donor liver transplantation in hepatocellular carcinoma patients with portal vein tumor thrombus: A multicenter study
    Yu, Jiongjie
    Zhuang, Li
    Liu, Peng
    Liu, Zhikun
    Ling, Sunbin
    Deng, Yinan
    Li, Jianhua
    Yang, Bo
    Chen, Zhishui
    Wang, Zhengxin
    Zang, Yunjin
    Yang, Yang
    Zheng, Shusen
    Xu, Xiao
    EJSO, 2022, 48 (01): : 121 - 132